<DOC>
	<DOCNO>NCT00514007</DOCNO>
	<brief_summary>Multicenter , open-label , phase 1 , cohort dose escalation study determine Maximum Tolerated Dose ( MTD ) Once Daily ( QD ) Twice Daily ( BID ) schedule .</brief_summary>
	<brief_title>Study Continuous OSI-906 Dosing</brief_title>
	<detailed_description>Multicenter , open-label , phase 1 , cohort dose escalation . The study open QD schedule , initiation BID schedule occur observation clinically significant related toxicity ≥ grade 2 QD schedule . Dosing initiated Day 1 daily dose ( either QD BID ) continue 21 day . Once recommended phase 2 dose determine BID schedule , 2 expansion cohort open : 1 ) Biomarker Expansion Cohort patient locally advance metastatic colorectal cancer 2 ) Diabetic Expansion Cohort patient advance solid tumor active Type 2 diabetes mellitus require insulin insulinotropic therapy . This study currently recruit Biomarker Diabetic Expansion Cohorts .</detailed_description>
	<criteria>Histologically cytologically document malignancy advance and/or metastatic refractory establish form therapy effective therapy exists . Patients Biomarker Expansion Cohort must histologically documented colorectal cancer locally advance metastatic refractory establish form therapy . These patient must archival tissue available lesion accessible biopsy Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 02 , life expectancy ≥ 12 week Prior chemotherapy permit provide minimum 3 week elapse . Prior tyrosine kinase inhibitor therapy permit . Patients must recover treatmentrelated toxicity ( exception ) prior registration Prior hormonal therapy permit provided discontinue prior registration ( exception prostate cancer patient hormone therapy least 3 month ) Prior radiation therapy permit provided patient recover toxic effect . A minimum 21 day must elapse unless radiotherapy palliative nonmyelosuppressive Prior surgery permit provide wound healing occur prior registration Fasting glucose ≤ 125 mg/dL ( 7 mmol/L ) baseline ( patient except Diabetic Expansion Cohort ) . Patients Diabetic Expansion Cohort must fast glucose ≤ 150 mg/dL ( 8.3 mmol/L ) baseline . If patient Diabetic Expansion Cohort treat noninsulinotropic oral antihyperglycemic therapy , dose must stable ≥ 4 week prior registration Potassium , calcium , magnesium must within normal limit ( WNL ) . Electrolyte abnormality permit clinically significant treatment abnormality initiate prior Day 1 Neutrophil ≥ 1.5 x 10^9/L , Platelet ( PLT ) ≥ 100 x 10^9/L ; bilirubin ≤ 1.5 x upper limit normal ( ULN ) , AST ALT ≤ 2.5 x ULN ≤ 5 x UNL patient document liver metastasis ; creatinine ≤ 1.5 x ULN Accessible repeat dose followup , include pharmacokinetic sampling Patients must practice effective contraceptive measure throughout study Provide write informed consent History kind stroke History psychiatric condition might impair patient 's ability provide inform consent participate History allergic reaction attribute similar compound study drug . Any type active seizure disorder Previously diagnose brain metastasis Concurrent anticancer therapy Active uncontrolled infection serious illness medical condition could interfere participation Pregnant breastfeeding female Documented history diabetes mellitus ( patient except Diabetic Expansion Cohort ) . Patients Diabetic Expansion Cohort may Type 1 diabetes mellitus Type 2 diabetes mellitus currently require insulinotropic insulin therapy Use drug risk cause QT interval prolongation within 14 day prior Day 1 study Use glucocorticoid within 14 day prior Day 1 study History significant cardiac disease unless well control ( include 2nd/3rd degree heart block , ischemic heart disease , QTc &gt; 450 msec , poorly control hypertension , congestive heart failure New York Heart Association ( NYHA ) Class II worse )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Renal cancer</keyword>
	<keyword>Advanced Cancer</keyword>
	<keyword>Metastatic cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Colorectal cancer</keyword>
</DOC>